Trexquant Investment LP boosted its position in Personalis, Inc. (NASDAQ:PSNL - Free Report) by 455.0% during the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 122,959 shares of the company's stock after purchasing an additional 100,804 shares during the quarter. Trexquant Investment LP owned about 0.14% of Personalis worth $432,000 at the end of the most recent quarter.
A number of other hedge funds and other institutional investors have also modified their holdings of PSNL. China Universal Asset Management Co. Ltd. grew its holdings in Personalis by 18.2% during the first quarter. China Universal Asset Management Co. Ltd. now owns 17,704 shares of the company's stock worth $62,000 after acquiring an additional 2,724 shares during the period. Point72 Asia Singapore Pte. Ltd. purchased a new position in Personalis during the 4th quarter valued at about $28,000. Stifel Financial Corp grew its stake in Personalis by 25.0% during the 4th quarter. Stifel Financial Corp now owns 25,000 shares of the company's stock valued at $144,000 after acquiring an additional 5,000 shares in the last quarter. Two Sigma Advisers LP lifted its holdings in shares of Personalis by 25.6% during the 4th quarter. Two Sigma Advisers LP now owns 34,300 shares of the company's stock valued at $198,000 after buying an additional 7,000 shares during the last quarter. Finally, Ameriprise Financial Inc. lifted its holdings in shares of Personalis by 38.3% during the 4th quarter. Ameriprise Financial Inc. now owns 34,407 shares of the company's stock valued at $199,000 after buying an additional 9,535 shares during the last quarter. 61.91% of the stock is currently owned by institutional investors.
Wall Street Analyst Weigh In
PSNL has been the subject of several analyst reports. BTIG Research set a $6.00 target price on Personalis in a report on Wednesday, August 6th. Guggenheim assumed coverage on Personalis in a report on Thursday, May 15th. They set a "buy" rating and a $6.00 target price on the stock. Wall Street Zen lowered Personalis from a "hold" rating to a "sell" rating in a research note on Saturday, August 9th. Finally, HC Wainwright reaffirmed a "buy" rating and set a $8.50 price target on shares of Personalis in a research report on Monday. Five analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, the company has an average rating of "Buy" and a consensus price target of $7.42.
Check Out Our Latest Research Report on Personalis
Personalis Price Performance
Shares of NASDAQ PSNL opened at $5.32 on Tuesday. Personalis, Inc. has a fifty-two week low of $2.83 and a fifty-two week high of $7.79. The stock has a market capitalization of $471.78 million, a PE ratio of -4.16 and a beta of 1.76. The business has a fifty day moving average price of $5.63 and a two-hundred day moving average price of $4.83.
Personalis (NASDAQ:PSNL - Get Free Report) last posted its quarterly earnings results on Tuesday, August 5th. The company reported ($0.23) EPS for the quarter, topping analysts' consensus estimates of ($0.25) by $0.02. Personalis had a negative return on equity of 47.57% and a negative net margin of 113.70%.The company had revenue of $17.20 million during the quarter, compared to analysts' expectations of $20.12 million. Personalis has set its FY 2025 guidance at EPS. Q3 2025 guidance at EPS. On average, equities analysts expect that Personalis, Inc. will post -1.4 EPS for the current year.
Personalis Company Profile
(
Free Report)
Personalis, Inc develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Personalis, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Personalis wasn't on the list.
While Personalis currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
